TECX Quote, Financials, Valuation and Earnings

The Cigna Group has a net margin of -- compared to Tectonic Therapeutic's net margin of 2.17%. Tectonic Therapeutic's return on equity of -- beat The Cigna Group's return on equity of 8.07%.

Tectonic Therapeutic has a consensus price target of $85.67, signalling upside risk potential of 238.68%. On the other hand The Cigna Group has an analysts' consensus of $362.31 which suggests that it could grow by 17.31%. Given that Tectonic Therapeutic has higher upside potential than The Cigna Group, analysts believe Tectonic Therapeutic is more attractive than The Cigna Group.

Tectonic Therapeutic has a beta of 1.289, which suggesting that the stock is 28.926% more volatile than S&P 500. In comparison The Cigna Group has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.338%.

Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cigna Group offers a yield of 1.81% to investors and pays a quarterly dividend of $1.40 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. The Cigna Group pays out 45.63% of its earnings as a dividend. The Cigna Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Tectonic Therapeutic quarterly revenues are --, which are smaller than The Cigna Group quarterly revenues of $65.7B. Tectonic Therapeutic's net income of -$17.7M is lower than The Cigna Group's net income of $1.4B. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while The Cigna Group's PE ratio is 25.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 0.36x for The Cigna Group. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of -- compared to Tectonic Therapeutic's net margin of --. Tectonic Therapeutic's return on equity of -- beat CEL-SCI's return on equity of --.

Tectonic Therapeutic has a consensus price target of $85.67, signalling upside risk potential of 238.68%. On the other hand CEL-SCI has an analysts' consensus of $7.40 which suggests that it could grow by 2142.42%. Given that CEL-SCI has higher upside potential than Tectonic Therapeutic, analysts believe CEL-SCI is more attractive than Tectonic Therapeutic.

Tectonic Therapeutic has a beta of 1.289, which suggesting that the stock is 28.926% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.414%.

Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Tectonic Therapeutic quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Tectonic Therapeutic's net income of -$17.7M is lower than CEL-SCI's net income of -$7.1M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Tectonic Therapeutic's net margin of -711.67%. Tectonic Therapeutic's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

Tectonic Therapeutic has a consensus price target of $85.67, signalling upside risk potential of 238.68%. On the other hand IGC Pharma has an analysts' consensus of $4.25 which suggests that it could grow by 1365.52%. Given that IGC Pharma has higher upside potential than Tectonic Therapeutic, analysts believe IGC Pharma is more attractive than Tectonic Therapeutic.

Tectonic Therapeutic has a beta of 1.289, which suggesting that the stock is 28.926% more volatile than S&P 500. In comparison IGC Pharma has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.346%.

Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Tectonic Therapeutic quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. Tectonic Therapeutic's net income of -$17.7M is lower than IGC Pharma's net income of -$1.8M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 17.05x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Treace Medical Concepts has a net margin of -- compared to Tectonic Therapeutic's net margin of -0.73%. Tectonic Therapeutic's return on equity of -- beat Treace Medical Concepts's return on equity of -46.9%.

Tectonic Therapeutic has a consensus price target of $85.67, signalling upside risk potential of 238.68%. On the other hand Treace Medical Concepts has an analysts' consensus of $10.91 which suggests that it could grow by 22.08%. Given that Tectonic Therapeutic has higher upside potential than Treace Medical Concepts, analysts believe Tectonic Therapeutic is more attractive than Treace Medical Concepts.

Tectonic Therapeutic has a beta of 1.289, which suggesting that the stock is 28.926% more volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

Tectonic Therapeutic quarterly revenues are --, which are smaller than Treace Medical Concepts quarterly revenues of $68.7M. Tectonic Therapeutic's net income of -$17.7M is lower than Treace Medical Concepts's net income of -$501K. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 2.65x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.